Terms: = Ovarian epithelial cancer AND MUC16, CA125, CA-125 AND Prognosis
312 results:
1. The Significance of Lymph Node Dissection in Patients with Early epithelial ovarian cancer.
Bao R; Olivier M; Xiang J; Ye P; Yan X
Ann Ital Chir; 2024; 95(4):628-635. PubMed ID: 39186355
[TBL] [Abstract] [Full Text] [Related]
2. External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.
Oufkir N; Rouzier R; Paoletti X; Bonneau C
J Ovarian Res; 2024 Jul; 17(1):152. PubMed ID: 39039554
[TBL] [Abstract] [Full Text] [Related]
3. The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial: study protocol for a randomized clinical multicenter trial.
Karlsson A; Lindahl G; Spetz Holm AC; Bergmark K; Dahm Kähler P; Fekete B; Ottander U; Öfverman C; Israelsson P; Falknäs L; Rosenmüller A; Tiefenthal Thrane M; Halili S; Lindahl TL; Jenmalm MC; Kjølhede P
Acta Oncol; 2024 Jul; 63():581-585. PubMed ID: 39037076
[TBL] [Abstract] [Full Text] [Related]
4. Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer.
Vázquez Rojo J; Vázquez Reguera J; Sánchez del Río A
Rev Colomb Obstet Ginecol; 2024 Mar; 75(1):. PubMed ID: 39013201
[TBL] [Abstract] [Full Text] [Related]
5. Effect of different treatment modalities on the prognosis of stage IV epithelial ovarian cancer: analysis of the SEER database.
Zhang S; Zhang H; Jia N; Suo S; Guo J
BMC Womens Health; 2024 Jun; 24(1):345. PubMed ID: 38877551
[TBL] [Abstract] [Full Text] [Related]
6. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
7. ovarian clear cell carcinoma with uterine intramural recurrence: Case report of ovarian clear cell carcinoma with fertility sparing treatment.
Chang TY; Yeh CY; Yang CY; Lin WC; Huang CC; Hung YC
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):90-94. PubMed ID: 38216278
[TBL] [Abstract] [Full Text] [Related]
8. Confirmation of the utility of the ca-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to ca125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract] [Full Text] [Related]
10. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
Zhang YL; Xia XK; Zhang M
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
[No Abstract] [Full Text] [Related]
11. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
Vilming B; Fallås Dahl J; Bentzen AG; Ingebrigtsen VA; Berge Nilsen E; Vistad I; Dørum A; Solheim O; Bjørge L; Zucknick M; Aune G; Lindemann K
Int J Gynecol Cancer; 2023 Dec; 33(12):1898-1905. PubMed ID: 38000795
[TBL] [Abstract] [Full Text] [Related]
12. Perspectives of Healthcare Professionals on the Management and Treatment of Advanced ovarian cancer in the UK: Results From the KNOW-OC Survey.
Fotopoulou C; Hall M; Lord R; Miller R; Sundar S; Roebuck N; Fildes L; Wesselbaum A; McCormack S; Hickey J; Ledermann J
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e1-e10. PubMed ID: 37923688
[TBL] [Abstract] [Full Text] [Related]
13. miR-29c-3p acts as a tumor promoter by regulating β-catenin signaling through suppressing DNMT3A, TET1 and HBP1 in ovarian carcinoma.
Zhao H; Feng L; Cheng R; Wu M; Bai X; Fan L; Liu Y
Cell Signal; 2024 Jan; 113():110936. PubMed ID: 37925048
[TBL] [Abstract] [Full Text] [Related]
14. A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (ca125, HE4, mesothelin).
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Clin Chem Lab Med; 2024 Feb; 62(3):530-539. PubMed ID: 37816681
[TBL] [Abstract] [Full Text] [Related]
15. Serum ca125 level as predictors of the efficacy of olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer.
Asano F; Momomura M; Morisada T; Tsushima K; Haruna Y; Shibuya H; Matsumoto H; Kobayashi Y
J Obstet Gynaecol Res; 2023 Dec; 49(12):2883-2888. PubMed ID: 37735981
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological Characteristics and prognosis of Diffuse Large B-Cell Lymphoma in Relation to ca-125 and CA 19-9 Expression.
Foda AAM; Atia T; Sakr HI; Abd Elaziz Ahmed Elnaghi K; Abdelhay WM; Enan ET
J Evid Based Integr Med; 2023; 28():2515690X231198315. PubMed ID: 37654084
[No Abstract] [Full Text] [Related]
17. An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China.
Chen S; Lu H; Jiang S; Li M; Weng H; Zhu J; Zhang T; Wang Y; Zhao W; Wu D; Shen Z; Yang Z; Zhou Y
BMC Cancer; 2023 Jul; 23(1):608. PubMed ID: 37391693
[TBL] [Abstract] [Full Text] [Related]
18. SOX9/NFIA promotes human ovarian cancer metastasis through the Wnt/β-catenin signaling pathway.
Lu R; Tang P; Zhang D; Lin S; Li H; Feng X; Sun M; Zhang H
Pathol Res Pract; 2023 Aug; 248():154602. PubMed ID: 37315400
[TBL] [Abstract] [Full Text] [Related]
19. Clinical value of serum and tissue AGR2 for diagnosis and prognosis in epithelial ovarian cancer.
Yan T; Wang H; Ma X; Cao J; Tong Y; Guo L; Lu R
Biomark Med; 2023 Mar; 17(6):325-336. PubMed ID: 37284743
[No Abstract] [Full Text] [Related]
20. Radiotherapy in recurrent ovarian cancer: updated results of involved-field radiation therapy.
Lee BM; Lee SJ; Kim N; Byun HK; Kim YB
Int J Gynecol Cancer; 2023 Jul; 33(7):1106-1111. PubMed ID: 37217239
[TBL] [Abstract] [Full Text] [Related]
[Next]
